%606012
Table of Contents
HGNC Approved Gene Symbol: DFNA18
Cytogenetic location: 3q22 Genomic coordinates (GRCh38) : 3:129,500,001-139,000,000
Bonsch et al. (2001) studied a 4-generation German family in which members had severe progressive nonsyndromic hearing loss. Onset was during the first decade of life and first involved the higher frequencies; in the following decades, the middle and lower frequencies became affected.
Bonsch et al. (2001) performed a genome scan with polymorphic microsatellite markers in a German family segregating nonsyndromic hearing loss and mapped the disorder, designated DFNA18, to a 10-cM region on 3q22 with a maximum 2-point lod score of 3.78 at theta = 0.0 for marker D3S1541. The DFNA18 locus was excluded from neighboring deafness loci DFNB15 (601869) and USH3 (276902), but the critical region overlapped with the locus for dystrophia myotonica-2/proximal myotonic myopathy (DM2; 602668) locus, in which hearing impairment has been described as part of the phenotype in some patients. Neurologic examination of the affected individuals of the DFNA18 pedigree gave completely negative results.
Exclusion Studies
Bonsch et al. (2003) excluded ZNF9 (116955), the gene mutant in DM2 (602668), as the disease gene in DFNA18.
Bonsch, D., Neumann, C., Lang-Roth, R., Witte, O., Lamprecht-Dinnesen, A., Deufel, T. PROMM and deafness: exclusion of ZNF9 as the disease gene in DFNA18 suggests a polygenic origin of the PROMM/DM2 phenotype. (Letter) Clin. Genet. 63: 73-75, 2003. [PubMed: 12519376, related citations] [Full Text]
Bonsch, D., Scheer, P., Neumann, C., Lang-Roth, R., Seifert, E., Storch, P., Weiller, C., Lamprecht-Dinnesen, A., Deufel, T. A novel locus for autosomal dominant, non-syndromic hearing impairment (DFNA18) maps to chromosome 3q22 immediately adjacent to the DM2 locus. Europ. J. Hum. Genet. 9: 165-170, 2001. [PubMed: 11313754, related citations] [Full Text]
HGNC Approved Gene Symbol: DFNA18
ORPHA: 90635; DO: 0110549;
Cytogenetic location: 3q22 Genomic coordinates (GRCh38) : 3:129,500,001-139,000,000
Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
---|---|---|---|---|
3q22 | Deafness, autosomal dominant 18 | 606012 | Autosomal dominant | 2 |
Bonsch et al. (2001) studied a 4-generation German family in which members had severe progressive nonsyndromic hearing loss. Onset was during the first decade of life and first involved the higher frequencies; in the following decades, the middle and lower frequencies became affected.
Bonsch et al. (2001) performed a genome scan with polymorphic microsatellite markers in a German family segregating nonsyndromic hearing loss and mapped the disorder, designated DFNA18, to a 10-cM region on 3q22 with a maximum 2-point lod score of 3.78 at theta = 0.0 for marker D3S1541. The DFNA18 locus was excluded from neighboring deafness loci DFNB15 (601869) and USH3 (276902), but the critical region overlapped with the locus for dystrophia myotonica-2/proximal myotonic myopathy (DM2; 602668) locus, in which hearing impairment has been described as part of the phenotype in some patients. Neurologic examination of the affected individuals of the DFNA18 pedigree gave completely negative results.
Exclusion Studies
Bonsch et al. (2003) excluded ZNF9 (116955), the gene mutant in DM2 (602668), as the disease gene in DFNA18.
Bonsch, D., Neumann, C., Lang-Roth, R., Witte, O., Lamprecht-Dinnesen, A., Deufel, T. PROMM and deafness: exclusion of ZNF9 as the disease gene in DFNA18 suggests a polygenic origin of the PROMM/DM2 phenotype. (Letter) Clin. Genet. 63: 73-75, 2003. [PubMed: 12519376] [Full Text: https://doi.org/10.1034/j.1399-0004.2003.630112.x]
Bonsch, D., Scheer, P., Neumann, C., Lang-Roth, R., Seifert, E., Storch, P., Weiller, C., Lamprecht-Dinnesen, A., Deufel, T. A novel locus for autosomal dominant, non-syndromic hearing impairment (DFNA18) maps to chromosome 3q22 immediately adjacent to the DM2 locus. Europ. J. Hum. Genet. 9: 165-170, 2001. [PubMed: 11313754] [Full Text: https://doi.org/10.1038/sj.ejhg.5200612]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM